Using gene therapy to express active telomerase (hTERT) in humans has the potential to treat many of the age related diseases, including Aging itself.
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse Aging.

Start Date17 Oct 2019

Sponsor / Collaborator

Libella Gene Therapeutics

NCT04133454 / Unknown statusPhase 1

Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Alzheimer's Disease: AAV- hTERT

Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse the development of the pathology of AD. It is expected to have a direct consequence on cognitive function and quality of life in patients with neurodegenerative diseases, such as AD.

Start Date10 Oct 2019

Sponsor / Collaborator

Libella Gene Therapeutics

NCT04110964 / Unknown statusPhase 1

Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Critical Limb Ischemia: AAV- hTERT

Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many diseases related to aging, including critical limb ischemia (CLI).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse the development of the pathology of CLI. It is expected to have a direct consequence on function and quality of life in patients with Peripheral artery disease (PAD); in this case a subgroup of patients with CLI, the worst presentation of PAD.

Start Date26 Sep 2019

Sponsor / Collaborator

Libella Gene Therapeutics

100 Clinical Results associated with AAV-hTERT

100 Translational Medicine associated with AAV-hTERT

100 Patents (Medical) associated with AAV-hTERT

Literatures (Medical) associated with AAV-hTERT

01 Feb 2024·International journal of biological macromolecules

Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro

Article

Author: Zhu, Ping ; Zhou, Yawen ; Shen, Juan ; Lu, Fengxia ; Zhu, Xiaoyu ; Lu, Zhaoxin ; Chi, Huibing

Type II L-asparaginase (ASNase) has been approved by the FDA for treating acute lymphoid leukemia (ALL), but its therapeutic effect is limited by low catalytic efficiency and L-glutaminase (L-Gln) activity. This study utilized free energy based molecular dynamics calculations to identify residues associated with substrate binding in Bacillus licheniformis L-asparaginase II (BLASNase) with high catalytical activity. After saturation and combination mutagenesis, the mutant LGT (74 L/75G/111 T) with intensively reduced l-glutamine catalytic activity was generated. The l-glutamine/L-asparagine activity (L-Gln/L-Asn) of LGT was only 6.6 % of parent BLASNase, whereas the L-asparagine (L-Asn) activity was preserved >90 %. Furthermore, structural comparison and molecular dynamics calculations indicated that the mutant LGT had reduced binding ability and affinity towards l-glutamine. To evaluate its effect on acute leukemic cells, LGT was supplied in treating MOLT-4 cells. The experimental results demonstrated that LGT was more cytotoxic and promoted apoptosis compared with commercial Escherichia coli ASNase. Overall, our findings firstly provide insights into reducing l-glutamine activity without impacting L-asparagine activity for BLASNase to possess remarkable potential for anti-leukemia therapy.

01 Jan 2024·Microbial physiology

Antioxidant and Anti-Inflammatory Activities of <i>Lindera glauca</i> Extracts

Article

Author: Ohk, Seung-Ho ; Park, Yi-Na ; Lee, Hyun Ju

Introduction: The current study investigated the antioxidant and anti-inflammatory effects of ethanol extracts from Lindera glauca twig (LGT) and leaf/stem (LGLS). Methods: The antioxidant activities were measured by total content of polyphenol and flavonoid, DPPH radical scavenging, and ABTS⁺ radical scavenging activity. To evaluate the anti-inflammatory effect in the LPS-induced RAW 264.7 cells, protein and mRNA expression of major inflammatory factors were analyzed using Western blot analysis and RT-PCR. Results: The total polyphenol content of LGT and LGLS was 88.45 ± 11.74 and 115.75 ± 7.87 GA mg/g, respectively. The total flavonoid content was 66 ± 2.89 and 74.33 ± 2.89 QE mg/g. Both LGT and LGLS showed high DPPH and ABTS⁺ radical scavenging activities. Neither LGT nor LGLS was cytotoxic to RAW 264.7 cells. The anti-inflammatory activities were measured by LPS-induced RAW 264.7 cells. LGT and LGLS showed inhibition of the LPS-induced production of nitric oxide (NO), inducible NO synthase, cyclooxygenase-2 at the protein and mRNA levels, as determined by Western blotting and RT-PCR, respectively. In addition, the release of tumor necrosis factor-α and interleukin-6 mRNA expression levels of these cytokines was reduced by LGT and LGLS. Conclusion: These results suggest that LGT and LGLS extracts have potential for use as a functional antioxidant and anti-inflammatory ingredient in cosmetic industry.

01 Jan 2024·Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway

Article

Author: Alanteet, Alaa ; Alfayez, Musaed ; Alsanea, Sary ; Mahmood, Amer ; Alsaleh, Khalid ; Attia, Hala

This study aims to explore the anti-proliferative, pro-apoptotic, and anti-migration activities of liraglutide (LGT) in MCF-7 breast cancer (BC) cells in subjects with obesity, particularly its effects on the PI3K/Akt/mTOR/AMPK pathway. The role of AMPK/SIRT-1, an essential regulator of adipokine production, in the effect of LGT on the production of adipose-derived adipokine was also assessed. MCF-7 cells were incubated in conditioned medium (CM) generated from adipose-derived stem cells (ADSCs) of obese subjects. MCF-7 cells were then treated with LGT for 72 h. Anti-proliferative, pro-apoptotic, and anti-migration activities were investigated using alamarBlue, annexin V stain, and scratch assay, respectively. Protein levels of phosphorylated PI3K, p-Akt, p-mTOR, and p-AMPK were investigated using immunoblotting. Levels of adipokines in ADSCs were determined using RT-PCR before and after transfection of ADSCs using the specific small interference RNA sequences for AMPK and SIRT-1. LGT evoked anti-proliferative, apoptotic, and potential anti-migratory properties on MCF-7 cells incubated in CM from obese ADSCs and significantly mitigated the activity of the PI3K/Akt/mTOR survival pathway-but not AMPK-in MCF-7 cells. Furthermore, the anti-proliferative effects afforded by LGT were similar to those mediated by LY294002 (PI3K inhibitor) and rapamycin (mTOR inhibitor). Our results reveal that transfection of AMPK/SIRT-1 genes did not affect the beneficial role of LGT in the expression of adipokines in ADSCs. In conclusion, LGT elicits anti-proliferative, apoptotic, and anti-migratory effects on BC cells in obese conditions by suppressing the activity of survival pathways; however, this effect is independent of the AMPK/SIRT1 pathway in ADSCs or AMPK in BC cells.

News (Medical) associated with AAV-hTERT

26 May 2021

·www.globenewswire.com

Global Gene and Cell Therapies Targeting CNS Disorders

Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Gene and Cell Therapies Targeting CNS Disorders - Market Insights and Market Forecast - 2026" report has been added to ResearchAndMarkets.com's offering. This 'Gene and Cell Therapies targeting CNS Disorders - Market Insights and Market Forecast - 2026' report delivers an in-depth understanding of the market trends of Gene and Cell Therapies targeting CNS Disorders in in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Gene and Cell Therapies targeting CNS Disorders market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Gene and Cell Therapies targeting CNS Disorders market size from 2018 to 2026, in the 7MM. The report also covers the current Gene and Cell Therapies targeting CNS Disorders treatment practice, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential. Gene and Cell Therapies targeting CNS Disorders emerging drugs NurOwn (BrainStorm Cell Therapeutics) is is mesenchymal stromal stem cells based therapy secreting neurotrophic factors (MSC-NTF) cells. It is designed to target disease pathways in neurodegenerative disorders by effectively delivering NTFs directly to the site of damage. MSC-NTF cells are generated using autologous, mesenchymal stem cells (MSCs) that have been extracted from bone marrow, expanded and differentiated ex-vivo. The therapy is currently under clinical evaluation in phase III for the treatment of Amyotrophic lateral sclerosis (ALS) and in phase II for treatment of Multiple Sclerosis, Chronic Progressive. Neuro-Cells (Neuroplast) is an autologous cell preparation that aims to decrease inflammation and reduce cell death. Neuro- Cells is produced in a certified and patented closed system manufacturing process from bone marrow and is a registered Advanced Therapy Medicinal Product (ATMP). Based on these mechanisms, Neuroplast focuses on developing a stem cell therapy, which can inhibit the inflammatory processes following damaged/dying neural tissue cells and sees its Neuro-Cells as a disease-modifying therapy (DMT). Currently it is being evaluated in phase I and phase II/III clinical studies in treatment of Spinal Chord Injuries (SCI). Gene and Cell Therapies targeting CNS Disorders Drugs Uptake This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2026. The analysis covers Gene and Cell Therapies targeting CNS Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions. Gene and Cell Therapies targeting CNS Disorders Pipeline Development Activities The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Gene and Cell Therapies targeting CNS Disorders' key players involved in developing targeted therapeutics. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Gene and Cell Therapies targeting CNS Disorders emerging therapies. Key Topics Covered: 1. Key Insights2. Report Introduction3. Executive Summary4. Gene and Cell Therapies targeting CNS disorders: Overview4.1. Introduction to CNS Disorders4.2. Role of Cell and Gene Therapy in CNS Disorders4.3. Multiple Sclerosis4.4. Parkinson's disease4.5. Spinal cord injury4.6. Amyotrophic Lateral Sclerosis4.7. Huntington's disease4.8. Alzheimer's disease4.9. Spinal Muscular Atrophy5. Landscape Assessment5.1. Regulatory Scenario of Cell and Gene Therapies in the 7MM5.2. United States5.3. The European Union5.3.1. United Kingdom5.3.2. Germany5.3.3. France5.3.4. Italy5.3.5. Spain5.4. Japan5.5. Reimbursement Scenario of Cell and Gene Therapies in the 7MM5.5.1. United States5.5.2. United Kingdom5.5.3. Germany5.5.4. France5.5.5. Italy5.5.6. Spain5.5.7. Japan5.6. Mergers and Acquisitions5.7. Industry News and Policies by Regions5.7.1. Industry News5.7.2. Policies and Government Initiatives for Cell and Gene Therapies6. Marketed Products6.1. Zolgensma: Novartis7. Emerging Therapies for Amyotrophic Lateral Sclerosis7.1. NurOwn: BrainStorm Cell Therapeutics7.2. Engensis: Helixmith7.3. HYNR-CS inj: Corestem7.4. Q Cells: Q therapeutics7.5. VM202: Helixmith7.6. RAPA-501 Autologous T cells: Rapa Therapeutics8. Emerging Therapy for Multiple sclerosis8.1. NurOwn: BrainStorm Cell Therapeutics8.1.1. Product Description8.1.2. Product Developmental Activities9. Emerging Therapy for Spinal Cord Injury9.1. Neuro-Cells: Neuroplast9.2. Umbilical Cord Blood Mononuclear Cell: StemCyte9.3. FAB117-HC: Ferrer Internacional9.4. Human spinal cord stem cells: Neuralstem9.5. FAB117-HC: Ferrer Internacional10. Emerging therapies for Alzehimer10.1. itMSCs: Stemedica Cell Technologies10.2. AAV-hTERT: Libella Gene Therapeutics10.3. ST-501: Sangamo Therapeutics11. Emerging Therapies for Parkinson Disease11.1. VY-AADC: Hoffmann-La Roche11.2. Lomecel-B: Longeveron11.3. OXB-102: Sio Gene Therapies11.4. PR001: Prevail Therapeutics (Eli Lilly and Company)11.5. Neural Stem Cell-Derived Neurons: NeuroGeneration11.6. AAV2-GDNF: Brain Neurotherapy Bio (AskBio)12. Emerging Therapy for Huntington12.1. Intra-striatal rAAV5-miHTT: UniQure Biopharma12.1.1. Product Description12.1.2. Research and Development12.1.3. Product Developmental Activities13. Company Profiles For more information about this report visit

Gene TherapyCell TherapyAcquisitionCollaborate

100 Deals associated with AAV-hTERT

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Age related disease	Phase 1	CO	Libella Gene Therapeutics	17 Oct 2019
Alzheimer Disease	Phase 1	CO	Libella Gene Therapeutics	10 Oct 2019
Chronic Limb-Threatening Ischemia	Phase 1	CO	Libella Gene Therapeutics	26 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

AAV-hTERT

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation